- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01295736
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY (SEDUCE)
Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, prospective, longitudinal, randomized, comparative, double-blind, 2-parallel-arm, placebo-controlled study aimed to evaluate the efficacy of sildenafil 20 mg TID study on time to healing of DUs in SSc patients with ischaemic DUs.
Approximately 120 patients aged from 18 years and above will be allocated to receive either placebo or sildenafil 20mg TID during 90 days. All potential subjects will present with ischaemic digital ulcers complicating scleroderma. An eligible digital ulcer must be beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers), of ischemic origin according to the physician, and not over subcutaneous calcifications or bone relief.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69437
- Hôpital Edouard Herriot
-
Paris, France, 75010
- St Louis Hospital
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06000
- University Hospital, Nice
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, France, 67098
- Hautepierre Hospital
-
-
Bouches du Rhone
-
Marseille, Bouches du Rhone, France, 13915
- Nord Hospital
-
-
Calvados
-
Caen, Calvados, France, 14033
- CHU de Caen
-
-
Côte d'Or
-
Dijon, Côte d'Or, France, 21000
- CHU Dijon
-
-
Haute Vienne
-
Limoges, Haute Vienne, France, 87042
- CHU Dupuytren / dermatology
-
Limoges, Haute Vienne, France, 87042
- CHU Dupuytren / Médecine Interne
-
-
Ile de France
-
Bondy, Ile de France, France, 93130
- Jean Verdier Hospital
-
Paris, Ile de France, France, 75013
- La Pitié - Salpétriêre Hospital
-
Paris, Ile de France, France, 75014
- Cochin Hospital / Médecine Interne
-
Paris, Ile de France, France, 75014
- Cochin Hospital
-
Paris, Ile de France, France, 75571
- Saint Antoine Hospital
-
Paris, Ile de France, France, 75674
- Groupe Hospitalier Paris Saint Joseph
-
-
Ile et Vilaine
-
Rennes, Ile et Vilaine, France, 35203
- CHU de Rennes
-
-
Indre-et-Loire
-
Tours, Indre-et-Loire, France, 37000
- University Hospital, Tours
-
-
Isère
-
Grenoble, Isère, France, 38043
- University Hospital, Grenoble
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, France, 44000
- University Hospital, Nantes
-
-
Marne
-
Reims, Marne, France, 51092
- CHU de Reims
-
-
Martinique
-
Fort de France, Martinique, France, 97 261
- University Hospital, Fort de France
-
-
Nord
-
Lille, Nord, France, 59037
- University Hospital, Lille
-
-
Seine-Maritime
-
Rouen, Seine-Maritime, France, 76000
- University Hospital, Rouen
-
-
Somme
-
Amiens, Somme, France, 80000
- University Hospital, Amiens
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with systemic sclerosis (ScS) according to the classification criteria of the American College of Rheumatology or of "LeRoy" and "Medsger".
- ScS patient with at least one ongoing ischaemic hand digital ulcer at baseline (see below the eligibility conditions of a digital ulcer).
- Patient must have provided written informed consent prior to enrolment. Patient agrees to come to the follow up visits inside the protocol specified range.
- Relative to each DU: DU must be beyond the proximal interphalangeal joint, on finger surface, of ischemic origin according to the physician, and not over subcutaneous calcifications or bone relief.
Exclusion Criteria:
- PAH requiring PDE5 inhibitors or prostacyclin history of stroke, myocardial infarction or life threatening arrhythmia within the last 6 months
- severe cardiac failure (NYHA IV) or unstable angina within the last 6 months.
- hereditary degenerative retinal disorders non-arteritic anterior ischemic optic neuropathy or untreated proliferative diabetic retinopathy
- uncontrolled diabetes mellitus
- Patient with known severe lung obstructive disease (FEV1<70% on last available pulmonary function tests).
- severe hepatic impairment
- Patient with known impairment of renal function (serum creatinine > 2.5 ULN).
- Patient with severe malabsorption or any severe organ failure (e.g., lung, kidney) or any life-threatening condition.
- Patient who has had surgical sympathectomy performed in the previous 12 months.
- Patient with a history of upper extremity deep vein thrombosis or lymphedema within the previous 3 months.
- Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months.
- Patient having received a treatment with sildenafil for digital ulcers or pulmonary arterial hypertension within 3 months prior to inclusion.
- Patient having received a treatment with parenteral prostanoids (prostaglandin E, epoprostenol, treprostinil sodium or other prostacyclin analogs) within 3 months prior to inclusion.
- Patient having received a treatment with inhaled or oral prostanoids one month prior to inclusion.
- Patient with previous intolerance or allergy to PDE5 inhibitors or a history of multiple clinically significant allergies.
- Pregnant or lactating female.
- Patient with uncontrolled tachyarrhythmias or bradyarrhythmias, or placement of pacemaker or implantable defibrillator within 60 days prior to randomization.
- Patient with hemodynamic instability or systolic arterial pressure less than 90 mmHg and/or symptomatic orthostatic hypotension.
- Patient receiving all forms of prostacyclin or nitrates or nitric oxide donors in any form including Nicorandil.
- Patient receiving potent inhibitors of CYP3A4 such as ketoconazole, itraconazole, ritonavir.
- Patient with any condition that prevents compliance with the protocol or adhering to therapy.
- Patient who has donated blood during the previous month or intends to donate blood or blood products during the study or for one month following completion of the study.
- Patient under guardianship (including curators) or deprived of liberty.
- Patient presenting with an anatomic malformation of penis (such as an angulation, sclerosis of erectile tissue or "Lapeyronie's disease").
- Patient presenting with a disease which predisposes to priapism (such as sickle-cell disease, myeloma or leukemia).
- Patient presenting with at least one digital ulcer meeting the exclusion criteria (see below).
- Relative to each DU:
- Digital ulcer due to conditions other than scleroderma.
- Non ischaemic digital ulcer.
- Infected digital ulcer requiring systemic antibiotherapy.
- Digital ulcer requiring urgent surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Actif arm
Sildenafil 20mg TID during 90 days
|
Sildenafil 20 mg TID per os during 90 days
|
Placebo Comparator: Sugar pill
Placebo pills TID during 90 days
|
Placebo pills TID per os during 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
time to healing of ischemic digital ulcers (DUs) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the time to healing of ischemic DUs (2 mm at entry and > 1 month and <3 months old) in patients with scleroderma treated by sildenafil 20 mg TID versus placebo for 90 days.
Time Frame: 90 days
|
90 days
|
To evaluate the change in the number of ischaemic DUs between baseline and day 90.
Time Frame: 90 days
|
90 days
|
To evaluate the proportion of patients with complete healing of all DUs present at baseline at day 90.
Time Frame: 90 days
|
90 days
|
To evaluate the proportion of patients with complete healing of all DUs (baseline DUs and new DUs) at day 90.
Time Frame: 90 days
|
90 days
|
To evaluate the proportion of patients who do not develop any new DU after 28 days of treatment with the study drug up to day 90.
Time Frame: 90 days
|
90 days
|
To evaluate the change between baseline and day 90 in hand function and pain.
Time Frame: 90 days
|
90 days
|
To evaluate the proportion of patients with complicated DUs (infection, gangrene, amputation, DU requiring IV prostanoids) over the 90 days period of treatment.
Time Frame: 90 days
|
90 days
|
To evaluate the evolution of the severity of Raynaud's phenomenon between baseline and day 90.
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric HACHULLA, PU-PH, University Hospital, Lille
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-021135-13
- 2010_14 (Other Identifier: sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Scleroderma
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedSYSTEMIC SCLERODERMA | ALLOGENEIC MESENCHYMAL STEM CELLS | ADULTFrance
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
University Hospital, LilleRecruiting
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Boston UniversityRegeneron PharmaceuticalsCompletedSystemic Sclerosis | Scleroderma | Diffuse Systemic Sclerosis | Diffuse SclerodermaUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University Hospital, Strasbourg, FranceRecruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSystemic SclerodermaUnited States
Clinical Trials on Sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
Rambam Health Care CampusUnknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedErectile DysfunctionSingapore
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenCompletedBecker Muscular DystrophyDenmark
-
N4 Pharma UK Ltd.BDD Pharma LtdCompleted